Attend the Medicinal Chemistry Summit: USA (17–18 September 2018)
Announcing the Medicinal Chemistry Summit: USA, part of the Drug Discovery Series by Global Engage, taking place in Boston.
Global Engage is pleased to announce, as part of their Drug Discovery Series of events, the Medicinal Chemistry Summit: USA, which will be held on 17–18 September 2018 at the Hyatt Regency, Boston Harbour (MA, USA). This event will be the sister meeting to the successful European Medicinal Chemistry Summit of 2017.
Designed to attract experts working in all areas of medicinal chemistry, the summit has three tracks focusing on key issues, such as optimizing hit-to-lead quality and timescale, protein degradation, DNA encoded libraries, small molecule immuno-oncology research, structure-based drug design and the use of artificial intelligence in the drug discovery process.
This extensive two-day event will provide a forum to network, learn and engage with senior representatives of leading pharmaceutical and biotech companies worldwide. There will be 40 expert-led presentations, interactive panel and roundtable discussions exploring key issues, and a dynamic exhibition room filled with solution providers showcasing their technologies.
The agenda includes an extended panel discussion that will explore the future of medicinal chemistry, while seven roundtable discussions, led by experts, will enable a deeper investigation of subjects including DNA encoded libraries, artificial intelligence in medicinal chemistry and predictive toxicology – improving compound safety.
Expert speakers include:
- Andrew Phillips - President & Chief Scientific Officer, C4 Therapeutics (MA, USA)
- Mark Bunnage - Senior Vice President and Site Head, Boston Research, Vertex Pharmaceuticals (MA, USA)
- Subharekha Raghavan - Executive Director, HTE and Lead Discovery Capabilities, Merck Sharp & Dohme (NJ, USA)
- Stevan Djuric - Vice President, Discovery Chemistry & Technologies, & Distinguished Research Fellow, AbbVie (IL, USA)